Evidence map›Paper›PMID 41188982›Full record

ArticleEuropean journal of medical research2025

Ursolic acid suppresses gastric cancer by targeting the miR-27a-3p/Wnt/β-catenin signaling axis.

Fenfen Xiang, Rongrong Liu, Qing Gu, Mengzhe Zhang, Jiawen Qian, Jinpeng Li, Zixi Chen, Xiaoxiao Li, Yixin Chen, Jing Tian and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fenfen XiangLaboratory Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, China. pt2349@shutcm.edu.cn.
Rongrong LiuDepartment of Blood Transfusion, the Fourth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 511300, Guangdong, China.
Qing GuLaboratory Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, China.
Mengzhe ZhangLaboratory Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, China.
Jiawen QianLaboratory Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, China.
Jinpeng LiLaboratory Medicine, Huadu District People's Hospital of Guangzhou, Guangzhou, 510800, Guangdong, China.
Zixi ChenLaboratory Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, China.
Xiaoxiao LiLaboratory Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, China.
Yixin ChenLaboratory Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, China.
Jing TianLaboratory Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, China.
Rong WuLaboratory Medicine, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, China. pt46@shutcm.edu.cn.

Funding

the One Hundred Talents Project of Putuo Hospital, Shanghai University of Traditional Chinese Medicine 2022-RCQH-03the Science Technology Innovation Project of Putuo District Health System ptkwws202307
6 · The paper itself

Abstract

Gastric cancer (GC) is a common type of cancer known for its challenges in early detection and unfavorable prognosis. The pathway involving Wnt/β-catenin and the improper regulation of microRNAs (miRNAs), especially miR-27a-3p, are crucial in the advancement of GC. Ursolic acid (UA), which is a naturally occurring anticancer agent, shows promise in the inhibition of GC. Although UA's anticancer effects have been recognized, the underlying molecular mechanisms in GC remain incompletely defined. Our findings indicate that UA strongly restricts the expansion, motility, and invasive behavior of GC cells by dampening activity within the Wnt/β-catenin cascade. Treatment with UA lowered miR-27a-3p expression, and blocking this miRNA further curtailed tumor cell aggressiveness by restoring DKK2, which functions as a suppressor of Wnt-driven signaling. The protein under investigation showed lower expression in advanced tumors. Its expression in these advanced tumors correlated with better pathologic outcomes and survival prognosis. Thus, we can categorize this protein as a novel tumor suppressor in GC. Consistent with these in vitro results, in vivo assays demonstrated that UA effectively curtailed tumor development. Taken together, these findings indicate that UA restricts GC progression via modulation of the miR-27a-3p/DKK2/Wnt/β-catenin axis, providing mechanistic insights for potential therapeutic strategies.

Indexed as

MicroRNAsStomach NeoplasmsTriterpenesWnt Signaling PathwayAnimalsbeta CateninCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansIntercellular Signaling Peptides and ProteinsMaleMiceMice, Nudebeta CateninDKK2 protein, humanIntercellular Signaling Peptides and ProteinsMicroRNAsMIRN27 microRNA, humanTriterpenesUrsolic AcidDKK2Gastric cancermiR-27a-3pUrsolic acidWnt/β-catenin

Identifiers

PMID41188982
PMCPMC12584524

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.